Intensity modulated radiotherapy (IMRT) the white, black and grey: a clinical perspective  by BINDHU, Joseph et al.
Joseph Bindhu et al • Intensity modulat ed radiotherapy (IMRT) the wh ite, blac k and grey...
Intensity modulated radiotherapy (lMRT) the
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A BS TRA C T
The radiotherapy community has in the past few decades witnessed dramatic shift in the treatment
modalities from conventional 2-D radiotherapy to the now widely practiced 3-DCRT, IMRT and evolv-
ing IGRT. IMRT has generated so much interest because of it s unique dosimetric modulation to con-
centrate doses to the targets of interests while also being able to relatively spare neighboring normal
tissue. However IMRT is not the all in one solution for radiotherapeutic management of solid malig-
nancies. The current enthusiasm in IMRT most be tempered with an understanding of the complexi-
ties of IMRT planning, treatment delivery, quality assurance, monitoring and clinical limitations. The
widespread implementation of this technological innovat ion may have been a bit premature consider-
ing that clinical information regarding the same is still being generated. This article tries to give an
overview of the potential advantages/disadvantages of IMRT in the clinical set up and the few con-
troversies (Grey Zone) that are still being resolved. There is evidence to indicate that indiscriminately
used IMRT may even harm the patient or have an inferior therapeutic index to 3DCRT. This and other
pertinent issues will be covered by the authors in this short review of IMRT in clinical practice.
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INTRODUCTION
Current status of IM RT
IMRT is the most exciting technological and
conceptual advance in radiotherapy since the
introduction of CT based dose planning in late
1970's. The benefits of IMRT are correlated
to dose escalation, potential for improved 10-
coregional control and anticipated superior
treatment results. However most compelling
justification for this expensive time consum-
ing modality is its established ability of nor-
mal tissue sparing and improved quality of
life. These features make IMRT the treatment
of choice in clinical situations where there is a
clear cut relationship between dose delivered
and clinical response and where normal tissue
provide a constraint on its delivery. This is es-
pecially applicable to head and neck cancers
where it is being widely applied . A few other
common tumor sites that may fit into this cat-
egory include carcinoma prostate, cervix and
breast [1-9].
Prostat e cancer
This site to date provides the largest clinical
experience with IMRT. There is comparative
data to show benefit over 3DCRT in several
clinical issues [10].
Zelefsky et al have reported the largest
clinical experience with IMRT used for pa-
tients with localised carcinoma prostate. They
have also done a comparative study with 61
patients undergoing 3DCRT. Normal tissue
toxicity was considerably reduced. The 2 year
acturial risk for grade 2 bleeding was 2% for
IMRT vs 10% for 3DCRT(p<0.001) . An updat-
ed report by Zelefsky and colleagues evaluat-
ing 772 patients undergoing IMRT showed a
very promising 3 year acturial biochemical
control rate for favorable (92%), intermediate
(86%) and unfavourable risk patients (81%)
[11-12].
The SIB technique (Simultaneous Integrat-
ed Boost) with hypofractionated radiotherapy
with greater than 2 Gy/fraction is currently
being evaluated for its potential to improve
upon their results.
Head an d Neck cancer
The most convincing data of the superior
therapeutic gain achievable with IMRT are
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from tumors close to base of skull such as
Nasopharynx and Sinonasal cancers in which
a higher rate of local control and lower inci-
dence of complications have been documented
[13, 14]. In terms of clinical outcome reports
from University of California Sanfransisco
and Memorial Sloan Kettering Cancer Cen-
ter (MSKCC) show excellent locoregional
control, greater than 90% and substantially
lower rates of Xerostomia [15-16]. Additional
potential functional gains from IMRT com-
pared with conventional RT include improved
swallowing and speech , thus translating into
improvements in broad aspects of Quality of
life.
Clinical data on other Head and Neck sites
are still quite limited on account of small
numbers, heterogenous tumor sites and rela-
tively short follow up. Although providing the
preferred treatment for most Head and Neck
sites on account of less anticipated motion and
proximity to critical normal tissue; there are
situations where it may be less than optimal.
To cite a few clinical examples, Early Vocal
cord carcinoma with anterior comissure in-
volvement may risk having a geographical
miss on account of the dose characteristics of
low energy photons. In this situation conven-
tional radiotherapy may provide an equivalent
therapeutic index, as normal tissue toxicity
is not unduly compromised with the recom-
mended portals used for this stage . A welllat-
eralized T1 oral cavity lesion can be efficient-
ly treated with 3DCRT with a comparatively
lower dose if any to opposite parotid. IMRT
in such a situation would contribute atleast a
marginal low dose to the opposite side of the
face and neck (increased integral dose and
low dose volume).
The 3DCRT technique would have equiva-
lent clinical results with the advantage of be-
ing more time and cost effective.
Carcinoma Breast
Theoretically and practically, IMRT at this
site does provide some clinical benefit. It im-
proves dose homogeneity within breast tis-
sue in comparison to conventional/conformal
treatment.
When IMC/Axillary nodal regions are a
part of the clinical target volume, it can pro-
vide a comparatively better sparing of ipsilat-
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eraI lung/cardiac volumes. This may be even
more significant pertaining to left sided tu-
mors. IMRT studies with treatment of intact
breast has shown lower incidences of acute
and chronic skin reactions compared to ret-
rospective series. However several unsolved
issues prevent it from being the standard of
care. Specific measures may be required to
counteract the effect of breathing motion .Re-
spiratory gating is still not an accessible option
for majority of centers with IMRT facilities.
The improvement in dose homogeneity within
the target volume and restriction of high dose
to normal tissue , comes at the cost of subject-
ing contralateral lung to lower doses of RT not
normally irradiated. Weare now observing an
increasing incidence in younger patients who
may have many expected years of survival to
be accounted for by the increased incidence
of developing a secondary cancer [17]. With
current limited data on the long term risks of
2nd malignancy with IMRT it may be required
to limit IMRT to the subset of patients most
likely to achieve a therapeutic gain especially
considering the fact that 3D radiotherapy at
this site provides acceptable dose distribution
and limited normal tissue toxicity.
Gynecological cancer
IMRT is receiving increasing attention in the
treatment of these sites because of established
dosimetric advantages of normal tissue spar-
ing. In fact it can benefit over conformal/3D
technique in any situation/site where Tele-
therapy is being planned. Eg. Pelvic/Extended
Pelvic or Pelvic-Inguinal fields. The contro-
versialrole of IMRT include its ability to pro-
vide dose escalation in situations whereICBT
is not possible or suitable. [18-21].
A few special clinical settings where IMRT
may show some clinical benefit over 3D tech-
niques include management of recurrent dis-
ease in previously irradiated patients. It may
even have a limited role for palliation in situa-
tions where the target is very near to or wraps
around normal tissue, Eg. retroperitoneal le-
sions and paraspinal tumor/nodes. Of course
any treatement in the palliative setting should
be limited to a potential extended survival and
a risk for anticipated late effects .
An interesting concept being evaluated in
this set up include dose escalation for sus-
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tained palliation, for example patients with
localized bone metastasis or plasmacytomas.
Another theoretical concept is reducing the
toxicity of prophylactic cranial irradiation.
IMRTcould selectively spare the outer cortex
and hippocampus (cognitive function) when
considering prophylactic RT to the whole
brain as a component of CNSdirected therapy
in Leukemia protocols.
Although the entire brain is currently ir-
radiated most metastasis occurs in the water-
shed areas and grey white junctions [22].
IMRT in the set up of re-irradiation pro-
vides the ideal provision of extending the max-
imal feasible dose while sparing normal tissue
toxicity. The promising results of a few re-ir-
radiation series (using 3D conformal RT) was
mainly compromised by unacceptable toxicity
and risk of reducing quality of life [23].
However the current clinical scenario does
not find the time and cost function favorable
for using IMRT in these situation in routine
clinical practice.
I Wh ich Patients will benefit from IMRT?
This is a grey zone with many unanswered
questions. Long term clinical results of IMRT
have only began to emerge. It is still to early to
recommend IMRT as the standard of care. In
terms of curative management of malignancy,
the most important caveat of IMRT is its po-
tential for dose escalation. Significant clinical
results are available to suggest that dose esca-
lation with IMRT dose translate to improved
local control in carcinoma nasopharynx and
carcinoma prostate. The escalation of dose by
simultaneous integrated boost (SIB) to a tu-
mor dose of 76 gray for treatment of locally
advanced nasopharyngeal carcinoma has
shown good short term outcomes [24]. Local
control and overall survival reported are 96%
and 92% which is significantly higher than
that anticipated for similarly treated disease
with 2D/3D technology. The excellent local
control rates may to a certain degree be at-
tributed to the better coverage made possible
with IMRT, especially for retropharyngeal,
base of skull and medial aspects of nodal vol-
ume [25]. There is positive evidence to show
that increasing dose for prostate radiotherapy
from 70 to 78 Gy in intermediate and high risk
prostate cancer would translate to better local
control [26]. In addition dose's of 81 Gy have
resulted in a 7%positive biopsy rate compared
to 45%with lower doses.
The following table may suggest a few limi-
tations of IMRT in the clinical set up. Patients
who will definitely benefit from IMRT.
II Grey Zone
Patients whose cancers may have equivalent
or better result with 3DCRT. E,g: Brain tu-
mors, localized early oral/oropharyngeal can-
cer requiring ipsilateral treatment.
III Patients who may be harmed by IMRT
1. Pediatric malignancies with good antici-
pated long term survival rates. The nearly 2
times increased potential for second malig-
nancies cannot be ignored .
2. Adult tumors in younger age group with
long term anticipated survival rate Eg Carci-
noma breast, Lymphoma.
3. Thoracic lesions when gating and other
respiratory movement control methods are
not being integrated. In this scenario there
is a significant risk of geographical miss. The
type of margins required to contour, the antic-
ipated movements negate the benefit of dose
conformation.
Considering the high cost of treatment,
longer and more intensive physician, physi-
cist, technologist and machine time and effort
involved in IMRT planning and delivery it is
critical that patients best benefited should be
identified and those who are not be realisti-
cally offered alternative treatments.
The Role of Imaging
The need for accurate determination of larger
volume and geometry of the organs at risk
(OAR) in IMRT cannot be over emphasized.
The dosimetric advantages of IMRT can be
clinically realized only if the anatomical
boundaries are precise. Early accurate delin-
eation of target and contouring of OARcan be
achieved with CT imaging in most situation.
A generalized overview of the role of image
fusion is given in table 2.
Will functioning imaging make a
difference?
Considerable data is available for IMRT in
Head and Neck sites to suggest 14-20% of re-
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Table 1. A fe"""limitations of IMRT in the clinical set up
Sino
1
2
3
Cornrnenu
Clinical evideqce of dose dependent response.
Conformal dose-djstribution required, not achieved with 2DCRT
Avoidance of criticerilstructure and lestoxicity desired
Application
Nasopharynx Ca Prostate
Paraspinal Lesion Concave targets.
Gynecological malignancies Ca Rectum.
Table 2. A generalized overview of the role of image fusion
Imaging modality for integration
in IMRT planning
Computed Tomography
MRI
Functrioanllmaging [27]
PET: [181 FDG [28, 29, 30]
Clinical role
Integration of additional data to that of CT
simulation
Superior contrast resolution for soft tissue.
MRI in anyarbitrary plane allows for cross
reference of tumor dimension. Studiesof MRI
integration in planning of brain tumor show
significant reduction in interobserver differ-
ences.
Provides information on activities and func-
tional mapof the brain.
Provides a biological target volume (BTV).
This allows for CTV identification and dose
restriction/escalation depending on the ad-
ditional informationconveyed.
Comment/limitation
Pre-treatment size specification when tumor
shrinkage has occurred with neoadjuvant CT.
MRI images may be subject to geometric dis-
tortion dueto patient and respiratory move-
ment.(Long imaging time).Bone is imaged
negatively and maynot bedistinguished from
air space. Image fusion may not be accurate
and occasionally not feasible if comparable
imaging set up is not reproduced.
Betterdelineation of the brain, tumorsand
functional areas.
FDG 18 PET may identify
1) Moreextensive locoregional disease
expanding CTV / PTV coverage.
2) Identify smaller volume of GTVlexciuding
doubtful lymphadenopathy, benign tissue ex-
ample atelectasis and necrosis thus restricting
tumor and planning target volume
currences occ ur as margina l with same sites
showing as high as 19% out field recurre nce .
FDG 18 PET could potentially prevent such
planning errors.
Howeve r contra ry to expanding volumes
analysis of 25 head and neck cases for IMRT
by Meze n E, Basi nouni et al [29] have shown
GTV PET was sig nificant ly sma ller tha n GTV-
CT (p-0.0022).
Paul ino et al [30] showed simi lar data in
75% of patients analyzed.
CTV CT/CTV PET - 1.7 to 2 (32.3% of cases)
GTV CT/GTV PET - 2.1 to 3 (22.2 % of cases)
This would ind icate that the shr inkage of
fields would have probably permitt ed a plan
better opti mized for norm al tissue sparing.
Considering both the aforementioned factors
FDG 18 PET would be a very useful planning
tool for des igning a mor e optimized plan. An-
other avenue of current attention is the use of
integrating image modalit ies for adap tive ra-
diotherapy. Bra hme et al [31] had suggested
that PET-CT could be used for adaptive radio-
therapy by measu r ing the mean dose deliv-
ery during the ea rly part of the treatment to
review the treatment plan . PET-CT for dose
escalation for metabolically active sites is cur-
rently speculative but does hold promise .
Defin ing the target Volu me :
Tig ht margi ns Vs Ge ograph ical mi s s.
P roper contouring of targets and normal tis-
sue is cr itica l to the usefulness of any IMRT
plan . Physicia n induced var iabi lity in contour-
ing ca n exist even in the sa me depar tment.
Over sta tement/under statement of treatm ent
margin s and volumes cloud lead to geographi-
cal miss and comprom ised cure . On the other
hand over gene rous margins may lead to poor
normal tissue spa r ing and reduce d benefits.
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A study of Phillippe Giraud, Sabine Elles,
Sylvie Felfre et al had analyzed 10 patients of
non-small cell lung cancer. The study com-
pared interobserver error
1. Between Radiologists & Radiation On-
cologists.
2. Senior Vs Junior radiation Oncologist
It was observed that mean GTV volume
was 133.6 em- vs 97.9 cm-. There was signifi-
cant contouring differences between the two
(p=O.I). Analysis of data from multiple cen-
ters show a much more significant difference
than that observed from interdepartmental
variations.
In comparison of Junior radiation Oncolo-
gist Vs Senior Radiation Oncologist, it was ob-
served that junior oncologist delineated small-
er volumes than senior radiation oncologist,
however the difference was not significant.
A few of the variations in both set-up could
have to a small degree be attributed to an in-
ferior knowledge of radiological anatomy than
to difficulties of visualization specific to the
patient, for example confusion between hilar
structures or mediastinal fat, tumor tissue Vs
artifacts in the lung.
The two most reliable methods to reduce
interobserver error (details previously ad-
dressed) is integrated image fusion having
structured departmental protocols.
As far as possible departments should pre-
pare guidelines with respect to identification of
tumor volume/extent for example image fusion
or collaborate to have a consultant radiologist
on call. It wouldbe recommended to strictly ad-
here to the broad outline of ICRU 50/ICRU 60
methodologyfor defining target volumes [34].
Preparing site wise protocols may aid in
avoiding interobserver variation and prepar-
ing a standard radiotherapy treatment plan.
Some of the pitfalls encountered in IMRT
contouring include those mentioned in table
3.
IMRT contouring is admittedly time con-
suming with a minimum of 1-3 hrs of physicist
time involved. The current generation of auto-
segmenatation tools have their limitations and
should not be used indiscriminately. An ex-
ample of some of the errors involved includes
contouring of irregular volumes. Margin for
structure when auto-segmented may not be
uniform in all cuts. There may be a 5 mm to 15
mm variation from the margin specified in the
command. Auto segmentation of spinal cord
often results in inclusion of the entire spinal
canal. This prevents giving a realistic margin
when adding organ at risk margins.
So although these tools help to reduce plan-
ning time, they should be implemented with
caution and be substantiated with cut by cut
review of contoured images of targets, mar-
gins and normal tissue.
Choosing an ideal margin ClV - PlV
The CTV - PTV margin aims to account for
patient setup uncertainty and internal organ
motion. Regions with minimal anticipated
internal organ motion and good immobiliza-
tion like brain/head and neck sites, the mar-
gins can afford to be narrow (3-5 mm). Areas
with more anticipated internal organ motion
like genitourinary and gastrointestinal sites
require more generous 1-2 em margins. But
do these guidelines fit every situation? Prob-
ably not. Internal organ motion can vary from
patient to patient (anxiety may alter respira-
tory rhythm and bowel habits determine GI
motility). Set up uncertainties may also differ
depending on the immobilization system or
set up direction/mounting used at a particu-
Table 3. Some of the pitfalls encountered in IMRT contouring include
Tumor/Target Volume
GTV
CTV1/CTV 2
Recommendation
Gross evaluable extentof tumoraided by integrated
image fusion .
Margins for these volume areguidedbyclinical risk
of microscopic disease asindicated bythe biology
andstage of the tumor. Considerable interpretative
errors can occur in terms of treatment decision as
well asidentification of high risk/low riskvolume.
Comments
Considerable interobserver variation.
: Specific Guidelines for individual sites often do not
: exist. The few guidelines that areavailable often
: will have to betailored to the clinical situation. This
: makes mostplans difficult to compare for clinical
: data.
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SIB and its variants
SIB or SimultaneousIntegrated Boost may now
be considered the strategy of choice for IMRT
for most centers. This fractionation scheme
aims to deliver several different dose levels to
tumor (higher) and normal tissues (lower) in
single treatment session. That is to say that in
each fraction dose to tumor, elective CTV and
normal tissues will be different. SIB may be de-
signed in 2 types of formats. In the more com-
monlyused one the target is planned to get con-
ventionalfractionationwhile the simultaneously
irradiated CTVI and CTV2 will get compara-
tively lower dose per fraction. Normal tissue at
risk will be receiving an even lower dose/frac-
tion. Disadvantage of this plan is the uncertain
radiobiological benefitof deliveringless'than 1.8
Gy per fraction to subclincal disease.
The second strategy would involve deliv-
ering greater than 2 Gy/Fraction dose to the
primary (hypo fractionation) target volume
maintaining normal tissue at conventional
doses: Although providing the benefit of bio-
logical dose escalation, this plan has a risk of
unanticipated complication. The hypofraction-
REVIEW ARTICLE
lar institute. Taking these uncertainties into IMRT fractionation schedules:
consideration, there is a need to create an in- Pros & Cons
stitutional protocol for CTV- PTV margin for What fractionation to choose?
various sites. An institution population based The fractionation designs mainly incorporat-
formulation can be considered to provide the ed into clinical practice include IMRT boost
most ideal treatment margin. Marcel Van protocols and SIB (Simultaneous integrated
Herk, Peter Remeijer et al have shown from a boost) and its variations Example of IMRT
population based analysis of patients in their boost plans include:
institute that a correct target dosage can be a) Initial phase - 30CRT + IMRT boost
reasonably achieved by computing the ideal b) Initial phase IMRT + IMRT boost (plan -2)
margin from analysis of systemic and random The theoretic disadvantage of these boost
errors. Large execution errors (random) lead protocols is that a large part of the dose deliv-
to CTV under dosage for a large number of ered in phase I, uses larger fields and there-
patients while large preparation errors (sys- fore the dose conformation achieved may not
temic) lead to a large under dosage to some provide additional benefit to normal tissue
patients. To ensure a minimum dose of 95% to sparing. For example in considering Head and
the CTV of 95% of patients a margin between Neck treatment plans.
CTV and PTV is required of 2.5 times the to- - Objective of keeping spinal cord below 45
tal standard deviation of preparation-(system- Gy is often not met.
atic) errors plus 1.64 times the total execution - Sub clinical disease gets more than the
(random errors) combined with the penumbra planned dose of 50-54Gy.
width minus 1.64 times the SO describing the - Although dose to parotids will be compara-
penumbra width. Because the margins ex- _ .tivelyless than conventional plans; desired
eludes rotational errors it might be considered dose tolerance limits are often exceeded.
as the lower limits for safe radiotherapy. -» '0 This would dilute the anticipated benefit of
The total PTV margin can be represented IMRT.
as MPTV =a2: + () P f3 [32,37]
M PTV - ptv margin
f3 - 95 %of cases is 1.64
() - total SO of all treatment execution (ran-
dom) variations, (organ motion () m and set up
error () s combined with the penumbra () p.
a - the specific value of a for 90% confidence
in 30CRT is 2.5.
Thus the mathematical formulation can an-
ticipate the optimal CTV - PTV margin that
can be instituted as a departmental protocol
for that particular site. The alternative would
be to customize the treatment after evaluat-
ing patient related set up errors during the
first week of treatment. The downside of this
is replanning may be required and the patient
might miss the optimal treatment prior to fi-
nalizing the margin.
Generation of adequate margins for nor-
mal organs at risk may be required to ac-
commodate for sharp dose gradient in IMRT,
especially considering the high radical dose
prescribed [33]. Current work is focused on
assessing normal tissue organ motion on serial
CT scans and anticipating ,the internal organ
motion components.
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ation although beneficial toward tumor control
carries a risk to the embedded normal tissue.
The choice of SIB should therefore take into
considerationthe clinical outcome data.
Several recent studies [35-39] have sug-
gested that alpha /beta values for prostate
is comparatively low with the probability
of benefiting from hypo fractionation (SIB
scheme 2). Considering the above; in principle
IMRT provides an easier more efficient form
of IMRT delivery with benefit of single plan,
shorter duration of treatment and avoidance
of errors associated with field matching and
dosimtereic uncertainties of combining with
electrons.
Plan evaluation:
Dose distributions: To be or not to be.
IMRT plan evaluation differs from 3D plan
evaluation in several clinical aspects that
should be evident to physician at the time of
evaluation. Notable is the trade off between
conformity and dose heterogeneity. If the pri-
ority is conformity one may have to accept
considerable dose heterogeneity. An other
factor that may contribute towards the lat-
ter would be increased concavity of target. A
slice by slice evaluation of dose distribution
in comparative 3DCRT and IMRT plans often
reveal a larger number of hotspots within the
target often greater than 110%. Unexplained
hotspots may also be thrown on normal tis-
sue contoured as well as other non contoured
area within the fields. Fine tuning of the treat-
ment plan would be more efficient and faster
if there is clear cut guidance from the physi-
cian as to what goals have more importance
and where and how doses can be permissibly
compromised.
Is the re a better alternative?
Treatment delivery with IMRT is not without
its drawbacks. The treating physician should
be realistic about the additional 1.5 to 2 times
dedicated effort and time required for treat-
ment planning, evaluation, delivery and qual-
ity assurance compared to conventional and
3D treatment plans. As mentioned previously
large volumes are being exposed to low doses
and with additional risk of head leakage, neu-
tron production and scatter with its attendant
greater risk of second malignancies [40-43].
Considering the above IMRT should be se-
lectively instituted in situations with a more
than marginal benefit either in terms of dose
parameter achievable or normal tissue sparing
and preferably with both parameters benefited.
Whenever the target is well localized or lateral-
ized, it may be preferable to consider a 3D plan
as an alterative during plan evaluation. For ex-
ample a very early stage lateralized oral cavity
lesion may have better normal tissue sparing
(contralateral parotid receiving none or negli-
gible dose) and total tissue irradiated less with
comparative dose goals achieved to an IMRT
plan. In such situations it may be advisable to
go for the benefit of a 3D CRT plan.
Weighing the cost benefit
This has to be viewed from 2 angles . From a
patients' point of view, the cost of IMRT in
most cases is 70-75% more expensive than
3DCRT. With limited long term data avail -
able the physician is handicapped to provide
positive evidence of benefit and as mentioned
previously it may not be necessary to treat all
patients with IMRT. In addition to which ethi-
cal issues would arise considering machine
time dedicated to IMRT delivery. Would we
be delaying treatment of patients who may be
benefited by earlier 3D/2D plans?
What does the future hold?
At the foremost of current interest is the pos-
sibility of biological dose painting, integrated
fusion, functional imaging, targeting metabol-
ic activity, hypoxia, angiogenesis etc.
Incorporation of radiobiological indices
may allow for a more realistic choice regard-
ing dose fractionation. Various modes of IGRT
are being more popularly used with consider-
ations to further reduce the risk of set-up and
internal organ movement errors. The evolving
technology of 4DCRT, respiratory gated target
motion compensation and immobilization of
targets by breathing control during treatment
facilitate safe delivery of a highly conformal
escalated dose to the target minimizing mar-
gins required thus also further benefiting nor-
mal tissue sparing.
CONCLUSION
IMRT has shown clear cut dosimetric ben-
efits over conventional 2D/3DCRT treatment
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techniques both in terms of tumor dose con-
formity and normal tissue sparing. Clinical
data although still immature, is emerging to
suggest the enhanced therapeutic ratio and
possible survival advantage of this modality
of treatment. This benefit has been confirmed
in some sites with clear cut dose response
relationship for example Nasopharynx and
Prostate. However IMRT cannot be con-
sidered a universal solution and has a long
way to go before becoming the standard of
care. The prohibitive cost of this technology
will still make it unacceptable to majority of
cancer population that may require it. How-
ever it is the current baseline over which re-
search and development work is being con-
ducted . Exciting progress is being made in
the areas of biological imaging and targeted
dose delivery. And it may not be far to look
forward to their incorporation into clinical
practice.
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